The Journal of infectious diseases
Authors: Chen I, Diawara H, Mahamar A, Sanogo K, Keita S, Kone D, Diarra K, Djimde M, Keita M, Brown J, Roh ME, Hwang J, Pett H, Murphy M, Niemi M, Greenhouse B, Bousema T, Gosling R, Dicko A
The Journal of infectious diseases
Authors: Kelly JD, Barrie MB, Mesman AW, Karku S, Quiwa K, Drasher M, Schlough GW, Dierberg K, Koedoyoma S, Lindan CP, Jones JH, Chamie G, Worden L, Greenhouse B, Weiser SD, Porco TC, Rutherford GW, Richardson ET
AIDS (London, England) | Volume 32 of Issue 6
Authors: Carrico AW, Cherenack EM, Roach ME, Riley ED, Oni O, Dilworth SE, Shoptaw S, Hunt P, Roy S, Pallikkuth S, Pahwa S
OBJECTIVE
Microbial translocation and monocyte activation predict mortality in treated HIV. We examined whether substance use independently contributes to these pathophysiologic processes.
DESIGN
Cross-sectional study at baseline for a randomized controlled trial.
METHODS
HIV-positive, methamphetamine-using MSM with undetectable HIV viral load (less than 40 copies/ml) were enrolled. We examined if plasma biomarkers of monocyte activation and intestinal barrier integrity were associated with the following: reactive urine toxicology results (Tox+) for stimulants (i.e., methamphetamine or cocaine) and substance use severity measured by the Addiction Severity Index. Multiple linear regression models adjusted for age, antiretroviral therapy regimen, CD4 T-cell count, interleukin-6, and alcohol use severity.
RESULTS
The sample of 84 virally suppressed MSM had a median CD4 T-cell count of 645 cells/μl. Those who were Tox+ for stimulants displayed higher soluble CD14 (sCD14) levels (2087 versus 1801 ng/ml; P = 0.009), and this difference remained significant after adjusting for covariates (standardized beta = 0.23, P = 0.026). Greater substance use severity was also independently associated with higher sCD14 after adjusting for covariates (standardized beta = 0.29, P = 0.013). Being Tox+ for stimulants and substance use severity were not associated with soluble CD163 (sCD163) or intestinal fatty acid binding protein (iFABP) levels (P > 0.05).
CONCLUSIONS
Monocyte activation is one plausible mechanism by which stimulant use may increase clinical HIV progression.
View on PubMed
BMC medical education
Authors: Peluso MJ, Luckett R, Mantzor S, Bedada AG, Saleeb P, Haverkamp M, Mosepele M, Haverkamp C, Maoto R, Prozesky D, Tapela N, Nkomazana O, Barak T
American journal of respiratory and critical care medicine
Authors: Ernst JD
Journal of immunology (Baltimore, Md. : 1950)
Authors: Whatney WE, Gandhi NR, Lindestam Arlehamn CS, Nizam A, Wu H, Quezada MJ, Campbell A, Allana S, Kabongo MM, Khayumbi J, Muchiri B, Ongalo J, Tonui J, Sasser LE, Fergus TJ, Ouma GS, Ouma SG, Beck AA, Mulligan MJ, Oladele A, Kaushal D, Cain KP, Waller L, Blumberg HM, Altman JD, Ernst JD, Rengarajan J, Day CL, TBRU-ASTRa Study Group
Parasitology
Authors: Ogongo P, Kariuki TM, Wilson RA
PLoS pathogens
Authors: Chitre AS, Kattah MG, Rosli YY, Pao M, Deswal M, Deeks SG, Hunt PW, Abdel-Mohsen M, Montaner LJ, Kim CC, Ma A, Somsouk M, McCune JM
PLoS pathogens
Authors: Hogan LE, Vasquez J, Hobbs KS, Hanhauser E, Aguilar-Rodriguez B, Hussien R, Thanh C, Gibson EA, Carvidi AB, Smith LCB, Khan S, Trapecar M, Sanjabi S, Somsouk M, Stoddart CA, Kuritzkes DR, Deeks SG, Henrich TJ
The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
Authors: Vasquez JJ, Hussien R, Aguilar-Rodriguez B, Junger H, Dobi D, Henrich TJ, Thanh C, Gibson E, Hogan LE, McCune J, Hunt PW, Stoddart CA, Laszik ZG
